Neurocrine CEO Kevin Gorman says the yearly price of $63,300 for its new specialty drug is based on value to the patients.

Neurocrine CEO Kevin Gorman says the yearly price of $63,300 for its new specialty drug is based on value to the patients. Photo by Jamie Scott Lytle.

— Neurocrine Biosciences Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129